Abbott Laboratories 2014 Annual Report Download - page 27

Download and view the complete annual report

Please find page 27 of the 2014 Abbott Laboratories annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 80

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80

25
Guangzhou,
China
KingMed Diagnostics runs thousands
of immunoassay, clinical chemistry, and
molecular diagnostic tests every day. They
rely on Abbott’s integrated testing and data-
management solutions to provide results that
improve patient outcomes while reducing
overall costs.
In that sense, KingMed is just like thousands
of other Abbott diagnostics customers all
around the world. Today, healthcare providers
are looking for ever faster and more accurate
methods to evaluate and treat their patients.
Abbott’s diagnostics businesses — Core
Laboratory, Molecular and Point of Care —
oer distinctly dierent technologies and
solutions, but they share a focus on helping
healthcare systems detect health risks and
disease at earlier stages, improving treatment
and disease management, while diminishing
subsequent health problems and their
associated costs.
With a more than 60-year history in
diagnostics, we’re positioned for growth. We’re
expanding our presence in the core laboratory
market segment to improve the eciency,
speed, and accuracy of patient tests, while
managing the vast amount of information
flowing through the lab. We’ll leverage our
deep expertise in infectious-disease testing
to help improve the treatment of people
with viruses and unknown infections. We
are delivering new point-of-care testing
capabilities that help accelerate treatment
decisions. And we’re building our presence in
fast-growing markets like China to meet the
increased demand in those regions.
ABBOTT 2014 ANNUAL REPORT